(S)-4-Benzyl-2-Oxazolidinone | CAS:90719-32-7

We serve (S)-4-Benzyl-2-Oxazolidinone CAS:90719-32-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
(S)-4-Benzyl-2-Oxazolidinone

Chemical Name: (S)-4-Benzyl-2-Oxazolidinone
CAS.NO:  90719-32-7
Synonyms:(4S)-4-benzyl-1,3-oxazolidin-2-one

Molecular Formula: C10H11NO2
Molecular Weight: 177.20000

Physical and Chemical Properties:
Density: 1.0 g/cm3
Boiling point:321ºC
Melting point: 86-88 °C(lit.)
Flash point: 195ºC
Refractive index:  1.552

Specification:
Appearance:  White to off-white  Powder
Purity:≥99.0%
Individual:≤0.5%
Total:≤1.0%
Chiral Assay:≥99.5%
Specific rotation:-64±2°
Water:≤0.5%

Packing:
 25kg 1 cardboard drum or according to customer specified requirements
Storage:0-6 ° C refrigerated, sealed, dry place, in an inert gas environment.
Application:Intermediates of Agomelatine CAS:138112-76-2.



Contact us for information like (S)-4-Benzyl-2-Oxazolidinone chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(4S)-4-benzyl-1,3-oxazolidin-2-one physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(4S)-4-benzyl-1,3-oxazolidin-2-one Use and application,(4S)-4-benzyl-1,3-oxazolidin-2-one technical grade,usp/ep/jp grade.


Related News: Since first being reported in the city of Wuhan, where it is believed to have originated at a seafood market, the virus has not provoked unusual symptoms in people who have been diagnosed.Biphenyl-3-boronic acid manufacturer A GSK spokesman said it was not yet clear by when ViiV would be able to address the FDA’s concerns.3-bromo-2-fluorobenzaldehyde supplier The death toll in China rose to at least 304.methyl 4-chloropyridine-2-carboxylate,hydrochloride vendor Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML).Who is at risk of infection? People of all ages can be infected with the virus, but older people and those with pre-existing medical conditions are especially vulnerable to severe complications.